Haematological and obstetric aspects of antenatal diagnosis of β-thalassaemia: experience with 200 cases

A CAO, M FURBETTA, A ANGIUS, A XIMENES, C ROSATELLI, T TUVERI, M T SCALAS, A M FALCHI, G ANGIONI, AND F CAMINITI

From the 2nd Pediatric Clinic, and Department of Obstetrics and Gynecology, University of Cagliari, Cagliari, Sardinia

SUMMARY The results of 200 antenatal diagnoses in pregnancies at risk for homozygous β-thalassaemia, carried out on fetal blood samples obtained by placental aspiration in the second trimester, are described. Globin chain synthesis in the fetuses was measured by means of 3H-leucine incorporation and separation of the chains on carboxymethyl-cellulose columns. Fetal red cell enrichment was performed by NH4Cl-NH4HCO3 differential lysis of maternal cells or anti-i differential agglutination. Sufficient fetal blood for analysis was obtained in 97.5% of the cases. The overall fetal loss rate was 6.5%, but it declined from 10% in the first consecutive 100 cases to 3% in the last 100 cases. Fetal loss was the result of early or late intrauterine death or spontaneous abortion. Forty-two homozygous fetuses had no β-chain synthesis and one had a very low β/γ ratio (0.005). Of the pregnancies, 37 were terminated at parental request and four aborted spontaneously. Absence of β-chain radioactivity was confirmed in 12 abortuses with suitable cord blood samples for analysis. Two pregnancies with homozygous fetuses were not terminated, as one member of each couple was a devout Catholic. As expected, both infants developed Cooley’s anaemia. Follow-up of the 146 infants, diagnosed in utero as non-homozygotes, showed cerebral palsy in one and a small cutaneous needle injury in three. None of these developed homozygous β-thalassaemia. Even β-thalassaemia trait with a β/γ ratio of 0.046 ± 0.012 can be distinguished from normal, showing a β/γ ratio of 0.086 ± 0.019 with a high degree of certainty.

Through advances in fetal blood sampling1–5 and development of biochemical methods for analysis of globin chains or haemoglobin synthesis of fetal reticulocytes,6–9 in the last few years prenatal diagnosis of homozygous β-thalassaemia and other inherited haemoglobin disorders has been shown to be feasible and accurate.10–19

In many countries where thalassaemia is prevalent and there is no social or ethical attitude against termination of pregnancy, such as in Greece, Cyprus, and Italy, a great demand for antenatal diagnosis has arisen. Up to March 1980 at least 1100 pregnancies at risk, including our series, have been monitored in several centres around the world (Alter, 1980, personal communication).

The main problems encountered in the early stages of development of this technology concerned the fetal blood sampling with associated fetal loss and the analysis of placental samples containing low fetal red cell percentages.15

Here we report (1) the obstetric and haematological results of antenatal diagnosis in the first 200 consecutive pregnancies at risk for β-thalassaemia monitored in the Genetic Service of the 2nd Pediatric Clinic of Cagliari University, Sardinia, between May 1977 and November 1979, and (2) the follow-up observations carried out in the offspring of these pregnancies.

Methods

SUBJECTS

Two hundred and fifty-three couples at risk, either with previous affected children or identified by heterozygote screening, were counselled with particular emphasis on the early stage of development of this technology, the possibility of misdiagnosis or
fetal blood sampling failure, and the risk of fetal loss (approximately 10%). Of these, 200 decided on antenatal testing and 53 decided against, either because of ethical reasons or concern about possible complications. Of the 200 couples monitored, 113 had already had one or more affected children (retrospective diagnosis) and 87 had no affected children (prospective diagnosis) (Table 1). The affected offspring had homozygous β^0-thalassaemia in 107 cases, homozygous β^+thalassaemia in five cases, and sickle cell/β^0-thalassaemia in one case. In the remaining couples with no affected offspring, both members were high Hb A^2 β-thalassaemia carriers. The majority of these couples were probably at risk for β^0-thalassaemia, as this is by far the most common type of β-thalassaemia in Sardinia. 20

The diagnosis of the β-thalassaemia carrier state was based on reduced MCV and MCH (Coulter Counter model S, Hileal, Florida) and increased Hb A^2 levels (DE-52 microchromatography, according to Huisman et al 21). The thalassaemia type of the previous affected offspring was defined by globin chain synthesis analysis.22 Informed consent was obtained from each couple.

FETAL BLOOD SAMPLING
Fetal blood sampling was carried out by placental aspiration with a 20 gauge needle at 18 to 24 weeks’ gestation after placental localisation with ultrasound (Picker Echoview model 80L), as described elsewhere.24

Before placental aspiration, maternal venous blood was drawn for reticulocyte count, fetal haemoglobin stain, and ^3H-leucine incorporation. Fetal haemoglobin staining was repeated on a maternal blood sample within 7 hours of the procedure.

In the 17 Rh negative mothers with Rh + fathers, anti-Rh globulins (200 μg) were administered within 48 hours of the procedure, as it was not possible to carry out fetal red cell typing.

CELL SIZING
Samples containing blood-tinged amniotic fluid were collected in heparinised syringes and analysed immediately. Cell counts were performed with a Coulter Counter model ZBI. The presence of fetal red blood cells in the placental samples was rapidly determined by red blood cell volume analysis with a Coulter C-1000 Channelizer attached to a Coulter Counter model ZBI, as already described.10 To verify the results obtained, smears from the same samples were stained by the Betke-Kleihauer method28 and the fetal red cell percentage determined.

INCUBATION
Placental samples were incubated with ^3H-leucine as already described.10 An aliquot of maternal venous blood, drawn just before placental sampling, was treated in the same way.

FETAL RED CELL ENRICHMENT
Fetal red blood cells were concentrated by differential agglutination with anti-i serum (kindly provided by Dr Kan), according to Kan et al 14 or by NH_4Cl-NH_4HCO_3 differential lysis of maternal cells according to Boyer et al 24 and Alter et al 25 with slight modifications, as already described.26

In two cases fetal red cell concentration was carried out by differential agglutination with anti-AB serum.27 Lysate and globin preparation and CM-52 column radiochromatography were carried out by previously described methods.10

DIAGNOSIS
The radioactivity under each globin peak was integrated after subtraction of the residual baseline counts. The β/γ globin chain synthesis ratios were obtained either in samples with 80 to 100% fetal red cells, original concentration or obtained after enrichment, or calculated by extrapolation when a sufficiently high fetal red blood cell concentration (less than 80%) could not be obtained.

Extrapolation was made with at least three original placental samples or samples obtained in the anti-i purification steps with differing red cell percentages.

HAEMATOLOGICAL FOLLOW-UP
Globin chain synthesis analysis was carried out on cord blood of fetuses aborted with intra-amniotic PGF_2α-prostaglandin, whenever there were samples suitable for analysis.

Blood samples from newborn infants were tested by globin chain synthesis analysis and/or red cell indices determination (Coulter Counter model S) plus cellulose acetate, pH 8.4 (Helena Laboratories, Beaumont, Texas), and citrate agar gel, pH 6.2, electrophoresis. After 6 months the infants were restudied with the same tests plus Hb A^2 (DE-52 microchromatography according to Huisman et al 23) and Hb F quantification.28
Haematological and obstetric aspects of antenatal diagnosis of \(\beta\)-thalassaemia

Fetal losses of 3% were observed and followed. The infants born were examined at birth or at 6 and 12 months, or both.

Results

**Fetal Blood Sampling**

Sufficient fetal blood for analysis was obtained in 195 (97·5%) of the 200 cases tested (fig 1).

The needle was inserted 1 to 4 times and from 2 to 85 small samples of blood-tinged amniotic fluid were obtained. Placental aspiration was repeated twice in 26 subjects and three times in nine with a one-week interval between attempts (table 2).

**TABLE 2  Results of fetal blood sampling by placental aspiration**

<table>
<thead>
<tr>
<th>No of pregnancies monitored</th>
<th>Total</th>
<th>Anterior placenta</th>
<th>Posterior placenta</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sufficient fetal blood obtained at 1st attempt</td>
<td>160</td>
<td>79</td>
<td>81</td>
</tr>
<tr>
<td>At 2nd attempt</td>
<td>26</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>At 3rd attempt</td>
<td>9</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Failures</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

**TABLE 3  Fetal cell percentages in placental blood samples**

<table>
<thead>
<tr>
<th>No of cases</th>
<th>Total</th>
<th>Anterior placenta</th>
<th>Posterior placenta</th>
</tr>
</thead>
<tbody>
<tr>
<td>With 100% fetal blood</td>
<td>46</td>
<td>20</td>
<td>26</td>
</tr>
<tr>
<td>With fetal blood between 50 and 100%</td>
<td>81</td>
<td>39</td>
<td>42</td>
</tr>
<tr>
<td>With fetal blood &lt; 50%</td>
<td>68</td>
<td>39</td>
<td>29</td>
</tr>
</tbody>
</table>

**Follow-up of the pregnancies**

Thirteen fetal losses occurred after sampling, eight involving the anterior placenta and five the posterior. The losses were the result of intrauterine death within 10 days of the procedure in two cases, after 10 days in six cases, and of spontaneous abortion in five, two having maternal urinary infection (table 4).

The minor complications observed were as follows: premature delivery (two cases), hemiplegic cerebral palsy (one case), needle injury in the buttock or thigh (three cases), fetomaternal transfusion with a fetal blood loss of approximately 120 ml (one case).
TABLE 4 Complications after fetal blood sampling by placentocentesis

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Anterior placenta</th>
<th>Posterior placenta</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrauterine death</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Within 10 days*</td>
<td>6</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>After 10 days</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Spontaneous abortion</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premature delivery</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spastic palsy</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fetomaternal transfusion</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous needle injury</td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*After the procedure

TABLE 5 Fetal blood sampling failure and fetal loss after placentocentesis: early versus late experience

<table>
<thead>
<tr>
<th>No of consecutive monitored pregnancies</th>
<th>1–100</th>
<th>101–200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal loss rate</td>
<td>10%</td>
<td>3%</td>
</tr>
<tr>
<td>Failure rate</td>
<td>3%</td>
<td>2%</td>
</tr>
</tbody>
</table>

There was a steady decline of both fetal blood sampling failure and fetal loss rates from the beginning to the later stages (table 5).

FETAL RED CELL ENRICHMENT

Fetal red cell enrichment was carried out in all the samples, even those slightly contaminated with maternal cells. In 61 cases the enrichment was performed with anti-i differential agglutination of fetal cells and in 94 cases with NH₄Cl-NH₄HCO₃ differential lysis of maternal cells. In two cases, already reported, with maternal blood group O and paternal blood AB, differential agglutination with anti-AB serum was carried out.

In many cases both the enrichment procedures were used for checking the haematological results obtained with Ørskov lysis, as has already been reported.

In some cases in which a satisfactory fetal cell concentration with Ørskov lysis was not obtained, the same samples were successfully enriched with anti-i differential agglutination.

The samples enriched with anti-i serum had fetal red cell percentages varying from 6·7 to 92·1% and counts from 4·2×10⁶ to 725×10⁶. The final concentration was 26·7 to ~100%.

The samples enriched by differential lysis of maternal cells had fetal red cell percentages and counts ranging from 3·8 to 89·3% and from 5·10⁶ to 113·10⁶, respectively. The final concentrations were approximately 100% in all but 27 cases and the recovery was 20·2 to 100%. In the 27 cases with partial enrichment, the final red cell percentages varied from 42·9 to 96·9%.

HAEMATOLOGICAL RESULTS

Fig 2 shows representative chromatograms of normal, heterozygous, and homozygous fetuses. The β/γ ratios were obtained in 118 cases by globin chain synthesis analysis of practically pure fetal blood samples, as original concentrations or after Ørskov lysis or differential agglutination, and in 76 cases they were calculated by extrapolation using at least three different samples obtained after anti-i agglutination (51 cases) or original placental samples with differing fetal red cell percentages (25 cases).

Forty-two fetuses with a β/γ ratio of 0 and one with 0·005 were presumed to be β-thalassaemia homozygotes (fig 3).

Since globin chain synthesis analysis at birth was found to be inappropriate for the precise identification of β-thalassaemia heterozygotes, we divided the non-homozygous fetuses into two groups. One included normal and heterozygous fetuses defined by complete haematological assessment, including Hb A₄ and F determination after the stage of haematological maturity (4 to 12 months after birth), and the other (non-homozygotes) had only globin chain synthesis analysis at birth. Twenty-four fetuses, diagnosed as normal at follow-up, had β/γ globin chain synthesis ratios from 0·049 to 0·120 with a mean of 0·086±0·019. Fifty-four fetuses, identified as β-thalassaemia heterozygotes at follow-up, had mean β/γ ratios of 0·046±0·012.
with a range of 0.028-0.110. A statistically significant difference (p<0.0001) between mean β/γ ratios of normal and β-thalassaemia heterozygotes was found, with a small overlap of individual values.

The second group (non-homozygotes) showed β/γ ratios ranging from 0.028 to 0.142. They will be genotyped at follow-up examination. It is worth pointing out that the lowest value found in heterozygous fetuses was 0.028.

**TABLE 6 Haematological follow-up of 148 infants born after antenatal diagnosis**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal*</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>β-thalassaemia heterozygotes*</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Non-homozygotes†</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>Homozygotes‡</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

*With red cell indices, Hb A2 and F measurement at 4–6 months.
†Undefined genotype as these infants have not reached the stage of haematological maturity (4–6 months).
‡Diagnosed correctly in utero.

acetate pH 8.4 and agar gel pH 6.2 electrophoresis on cord blood or venous blood at 1 to 2 days, thalassaemia major was excluded in all the infants diagnosed in utero as non-homozygotes (table 6).

Seventy-eight infants, including all the offspring of pregnancies at risk for β*-thalassaemia, were followed up to haematological maturity (4 to 6 months). Of these, 30.7% were normal and 69.3% were β-thalassaemia heterozygotes. No misdiagnosis was made (table 6).

**Discussion**

This study, concerning a group of 200 pregnancies at risk for β-thalassaemia, monitored by fetal blood sampling with placentocentesis and globin chain synthesis analysis of fetal blood, shows that antenatal diagnosis of homozygous β-thalassaemia is feasible and accurate, with acceptably low failure and fetal loss rates, confirming and expanding previous studies.12 14 16–18

Fetal blood sampling by needling in the second trimester has a high degree of success with a failure rate of only 2.5%. Moreover, there was a decline in the failure rate from 3% in the first series of 100 cases to 2% in the second 100 cases examined, through the obstetrician gaining experience and the introduction of Ørskov lysis, which allowed successful analysis even with relatively low fetal red blood cell percentages (less than 5%). As we have already reported,16 17 there was a slightly higher success rate in posterior than in anterior placentas, as greater red cell percentages were obtained in the former.

Besides placental aspiration, fetal blood can be obtained by fetoscopy.4 15 18 31 Both techniques have a high degree of success,15 but placental aspiration requires less skill, facilities, and organisation. Therefore, it can be performed in underdeveloped countries where thalassaemia is more prevalent.

The fetal loss rate was 6.5%, slightly higher in anterior than in posterior placentas (fig 1). Interestingly, as was seen in the failure rate, the fetal loss rate had a continuous decline from 10% seen in the...
first 100 consecutive cases to 3% in the last 100 examined. This too may be partially attributed to the increased experience in fetal blood sampling gained by the obstetrician and partially to the introduction of Órskov lysis for fetal red cell concentration. In fact, with this technique the number of placental aspirations required have been minimised, because the procedure was stopped as soon as a minimum amount of fetal blood was obtained.

The fetal loss rate of 6.5% seen in our series is similar to the overall rate of 6.7% observed in approximately 1100 cases, including ours, studied in several centres around the world up to March 1980 (Alter, 1980, personal communication) and lower than the 9.5% noted by Matsakis et al22 in a group of 200 cases. In both these series sampling was carried out by needleing or fetoscopy.

In our pregnancies fetal losses resulted from early or late intrauterine death and spontaneous abortion. Consistent fetomaternal transfusion was very rare, being observed in 0.5% of the subjects.

Apart from fetal loss, no major adverse effect of the placentocenteses was seen in the mothers or the babies. A case of hemiplegic cerebral palsy was detected at follow-up, giving an incidence of 0.5%, slightly higher than the 0.25% figure already noted in a large series of newborns.23 It cannot be excluded that this complication resulted from the placental sampling. However, it should be noted that in this pregnancy needleing was performed easily and was successful at the first attempt with withdrawal of only two small placental samples.

The risk of physical injury to the fetus is real, as is shown by the placentocenteses needle injury found in three babies. However, from our experience the risk appears slight and the injuries minor. Finally, from the limited data collected to date, it seems that there was no major adverse effect of placentocenteses on child growth and development (unpublished observations).

Both anti-i differential agglutination and Órskov lysis may result in satisfactory fetal red cell enrichment, as has already been seen.14 15 Since the availability of high titre anti-i is limited and anti-i differential agglutination is inefficient in samples containing less than 5% fetal red blood cells, Órskov lysis could be considered the best method for fetal red cell enrichment. However, at times a satisfactory fetal red blood cell concentration could not be obtained with this method. It is worth noting that the samples in which Órskov lysis failed could be successfully enriched with anti-i.

The biochemical analysis of fetal blood with globin chain synthesis analysis seems to be extremely accurate. In the pregnancy at risk for sickle cell/β-thalassaemia, both βS- and βA-globin chain synthesis were readily demonstrated allowing a diagnosis of sickle cell trait.

Homozygous β-thalassaemia fetuses with no β-chain synthesis were clearly distinguishable from heterozygous fetuses in which the lowest β/γ ratio found was 0.028. Globin chain synthesis analysis in cord blood of aborted fetuses, whenever there was suitable blood for analysis, confirmed the absence of β-chain synthesis. Two cases which continued to term, in which no β-chain synthesis had been found in the second trimester, developed transfusion-dependent thalassaemia major with haematological findings consistent with homozygous β0-thalassaemia. It should be noted that the figure of 43 out of 200 fetuses with no β-chain synthesis is very close to the value of 1:4 expected for an inherited recessive disorder.

Finally, no misdiagnosis was made, as shown by the haematological and clinical follow-up study carried out in all cases where the homozygous state was ruled out.

Our experience with β-thalassaemia is rather limited, as only one homozygous fetus with a β/γ ratio of 0.005 was diagnosed in the second trimester. According to Matsakis et al,22 it appears that the upper limit for Hb A synthesis in fetuses with β+-thalassaemia major can be clearly separated from the lower limit in fetuses with β0-thalassaemia trait, as the ambiguous results occurring in 3% of the cases in his series were clarified by repeating the analysis after 2 to 3 weeks.

From our results it appears that the β-thalassaemia trait can be identified in the second trimester with a high degree of certainty. In fact, genotype assessment 6 months after birth showed only a slight overlap between normal and β-thalassaemia heterozygous fetal β/γ globin chain synthesis ratios.

Several technical problems may cause difficulties in antenatal diagnosis of β-thalassaemia. Among these is the presence of a γ variant comigrating with the β-chains, as was recently observed in our service,24 in which modification of the phosphate gradient allowed us to separate the β and γ variant chains and thereby diagnose antenatally a normal fetus which was confirmed after birth.

Besides benefit to individual couples, antenatal diagnosis of β-thalassaemia, when associated with carrier screening of people of child bearing age, has even greater benefits for society. In southern Sardinia, where our service is located, the annual birth rate of β-thalassaemia homozygotes declined from 1:213 live births in 1976 to 1:296 in 1978.

In conclusion, the results presented in this paper show that globin chain synthesis analysis of fetal blood obtained by placental aspiration can be used to monitor pregnancies at risk for homozygous
β-thalassaemia, as the biochemical analysis was very accurate and the fetal loss rate was found to be acceptably low. However, in order to minimise further the fetal loss rate, our project consists of monitoring pregnancies at risk with fetal blood sampling only when indirect diagnosis by DNA linkage (Bam HI and/or Gy–ÀY polymorphisms) analysis of amniotic fluid cells cannot be used.

We would like to thank Dr Y W Kan for his continuing advice and Rita Loi and Kathleen Stark for their excellent editorial assistance.

This work was supported in part by grants from Assesssorato Igiene e Sanità Regione Sarda, CNR subprogetto “Malattie Ereditarie dell’Eritrocito” contract number 80.0225.83 and NIH grant No RO5 HL-24173-03.

References


Requests for reprints to Professor A Cao, 2a Clinica Pediatrica, Università Studi Cagliari, Via Porcell 1, (C/P 251), 09100 Cagliari, Sardinia, Italy.
Haematological and obstetric aspects of antenatal diagnosis of beta-thalassaemia: experience with 200 cases.

A Cao, M Furbetta, A Angius, A Ximenes, C Rosatelli, T Tuveri, M T Scalas, A M Falchi, G Angioni and F Caminiti

*J Med Genet* 1982 19: 81-87
doi: 10.1136/jmg.19.2.81

Updated information and services can be found at: [http://jmg.bmj.com/content/19/2/81](http://jmg.bmj.com/content/19/2/81)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)